Hidradenitis suppurativa research hub
33 indexed studies · 20 currently recruiting
- authorisedTherapeutic use (Phase IV)
Adalimumab Treatment for Patients with Hidradenitis Suppurativa at high risk of Progressing to Severe Disease: An Unblinded Randomized, Controlled Trial
This clinical study tests whether a medicine called adalimumab can stop hidradenitis suppurativa from getting worse. Doctors want to see if treating high-risk patients earlier prevents severe, painful boils and scarring compared to standard treatments like antibiotic tablets and skin creams over two years.
Denmark - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
This study is looking at the long-term safety and effectiveness of a new medicine called bimekizumab for adults with moderate to severe hidradenitis suppurativa (HS). It's an extension of an earlier study, helping us understand how well the treatment works and if it causes any side effects over a longer time.
Germany · Ireland · Greece - recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
This study is looking at a medicine called secukinumab for people with moderate to severe hidradenitis suppurativa (HS). It aims to see how well the medicine works long-term and if it is safe, especially after people have already seen some improvement.
Austria · Croatia · Czechia - recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa – The CEDAR Study
This study is testing a new medicine, brensocatib, for adults with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy pill to see if it helps reduce painful skin lumps and swelling. Researchers want to know if it's safe and effective.
Germany · France · Spain - recruitingTherapeutic exploratory (Phase II)
Phase 2, randomized, double-blind, placebo-controlled study of IC0624 as first-line therapy in patients with active mild to moderate Hidradenitis Suppurativa (HS)
This study is testing a new medication called IC0624 for people with a skin condition called Hidradenitis Suppurativa (HS). It's comparing the new medicine to a dummy pill to see if it helps reduce HS symptoms over six weeks.
Germany - recruitingHuman Pharmacology (Phase I)- First administration to humans
A clinical study of MK-6050 in healthy people (MK-6050-001)
This study is looking at a new medicine called MK-6050 in healthy men. It's the very first time this medicine is being given to people. The goal is to see how safe the medicine is and what it does in the body. This is an early step in finding new ways to treat a skin condition called hidradenitis suppurativa.
Belgium - active not recruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
United States · Argentina · Australia - active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
United States · Argentina · Australia - recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled, proof of concept study assessing the efficacy and safety of an anti-TNF-OX40L NANOBODY® molecule, SAR442970, in participants with moderate to severe hidradenitis suppurativa
This study is testing a new medicine, SAR442970, for people with moderate to severe hidradenitis suppurativa (HS). It aims to see if the medicine is safe and helps improve HS symptoms and pain, compared to a dummy treatment.
Belgium · Netherlands · Sweden - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called Povorcitinib for people with moderate to severe hidradenitis suppurativa (HS). It compares the medicine to a dummy pill to see if it helps reduce HS symptoms and pain, and improves quality of life.
Poland · Germany · Bulgaria - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine, povorcitinib, for people with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy pill to see if it helps reduce HS symptoms and pain, and improve quality of life.
Belgium · Germany · Austria - recruitingTherapeutic exploratory (Phase II)
A parallel-group treatment, Phase 2, double-blind, placebo controlled study to evaluate the efficacy and safety of SAR444656 in adult participants with moderate to severe hidradenitis suppurativa.
This study is testing a new medicine, SAR444656, for adults with moderate to severe hidradenitis suppurativa (HS). We want to see if it's safe and helps reduce painful skin lumps and spots. Half the participants will get the new medicine, and half will get a dummy medicine, to compare the effects.
Spain · Greece · Germany - recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine, Izokibep, for people with moderate to severe hidradenitis suppurativa (HS). It compares Izokibep to a dummy medicine to see if it improves HS symptoms and is safe.
Hungary · France · Spain - recruitingPhase II and Phase III (Integrated)
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
This study is testing a new medicine, spesolimab, for people with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it helps reduce HS symptoms and if it's safe. Some people will get the new medicine, while others will get a dummy medicine (placebo).
Czechia · Germany · Portugal - active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine, remibrutinib, for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it's safe and effective compared to a dummy pill.
United States · Argentina · Austria - recruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
United States · Australia · Canada - recruitingPHASE2
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
This study is looking at a new medicine called Zasocitinib for adults with Hidradenitis Suppurativa (HS). Researchers want to see if it's safe, how well it works, and if people can tolerate it. HS causes painful bumps, usually where skin rubs together.
United States · Australia · Canada - recruitingPHASE2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study looks at a new medicine called SAR445399 for adults with moderate to severe Hidradenitis Suppurativa (HS). It aims to see if the medicine is safe and effective compared to a dummy treatment, and to find the best dose.
United States · Argentina · Australia - recruiting
Defects of Keratinocytes Function in Dermatologic Patients
This study looks at a skin condition called hidradenitis suppurativa (HS). Researchers want to understand how tiny skin cells called keratinocytes work when someone has HS. They hope this will lead to better treatments for HS, an often painful and challenging long-term condition.
Austria · Belgium · France - active not recruitingPHASE3
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
This study looks at the long-term safety of a treatment called bimekizumab for people with moderate to severe hidradenitis suppurativa (HS). It builds on earlier studies to see how well the treatment works and if it's safe over a longer period.
United States · Australia · Belgium - recruitingPHASE3
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
This study looks at new antibiotic treatments for moderate hidradenitis suppurativa (HS), a skin condition. Researchers want to see if these new combinations of antibiotics work better than standard treatment. It involves different antibiotic courses over several weeks to find the most effective approach.
France - active not recruitingPHASE2
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
This study is looking into a new medication called tulisokibart for people with moderate to severe hidradenitis suppurativa (HS). It aims to see if this new treatment is better than a dummy medicine (placebo) at reducing HS symptoms over 16 weeks.
United States · Argentina · Australia - active not recruiting
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
This study looks at how a medicine called secukinumab is used in real life for adults with moderate to severe hidradenitis suppurativa (HS). It aims to understand treatment patterns and what influences dose decisions over two years in Germany.
Germany - active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study is looking at a new medicine called sonelokimab for adults with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it's safe and effective compared to a placebo (a dummy medicine) in improving HS symptoms.
United States · Bulgaria · Canada - active not recruitingPHASE2
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
This study looks at a new drug, lutikizumab, for adults with moderate to severe hidradenitis suppurativa (HS). It focuses on people whose current treatments haven't worked well or who haven't tried certain biological therapies before. The aim is to see if lutikizumab can reduce HS symptoms and is safe to use.
United States · Australia · Canada - active not recruitingPHASE2
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
This study is testing a new medicine, brensocatib, for adults with moderate to severe hidradenitis suppurativa (HS). We want to see if it's safe and helps improve HS symptoms compared to a dummy medicine.
United States · Australia · Bulgaria - active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
This study is testing a new medicine called remibrutinib for people aged 12 and older with moderate to severe hidradenitis suppurativa (HS). It aims to see how well it works and if it's safe compared to a dummy pill.
United States · Argentina · Australia - recruitingPHASE3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
This study is looking at a cream for hidradenitis suppurativa (HS), a skin condition. It aims to see how well ruxolitinib cream works and if it's safe for people with mild to moderate HS. Some people will get the cream, others a 'dummy' cream.
United States · Bulgaria · Canada - recruitingPHASE3
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
This study looks at a new medicine called Bimekizumab for children and teenagers with moderate to severe Hidradenitis Suppurativa. It checks how the medicine works in the body and if it's safe.
United States · Germany · Poland - active not recruitingPHASE3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
This study is for people with moderate to severe Hidradenitis Suppurativa who have already been treated with Secukinumab in previous studies. It looks at whether continuing this medicine or stopping it works best long-term, and how safe it is.
United States · Argentina · Australia - recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study looks at how skin conditions like alopecia areata, vitiligo, and hidradenitis suppurativa affect daily life for teenagers and adults. Researchers want to understand the challenges these conditions bring to people all over the world.
Argentina · Canada · Colombia - enrolling by invitationPHASE3
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
This study looks at how safe and effective a new medicine, Sonelokimab, is for a long time in people with moderate to severe Hidradenitis Suppurativa. It's for those who have already been in similar Sonelokimab studies.
United States · Belgium · Bulgaria - authorisedTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medication called Zasocitinib for people with moderate to severe Hidradenitis Suppurativa (HS). Researchers want to see if it helps reduce HS symptoms and if it's safe. It's a 'Phase 2' study, meaning they are still exploring its effectiveness and safety.
France · Poland · Netherlands